Peptides are everywhere—from TikTok and Instagram to online wellness companies promising fat loss, anti-aging, muscle growth, and longevity. But are they safe? And are they right for everyone?

In this episode of The Medical Weight Loss Show, Dr. Andrea Walker discusses why she doesn't prescribe every trending peptide on the market and explains the importance of medical oversight, informed consent, and individualized care.

Learn why Retatrutide, CJC-1295, Ipamorelin, BPC-157, and GHK-Cu, and others should be considered carefully before using and discover why "research use only" should never be ignored.

Your health is too important to trust to social media trends. Before you inject anything into your body, make sure you know what's in it, where it came from, and whether it's truly appropriate for you.

Because when it comes to your health, safety should always come first.

If you are currently taking a GLP-1 like Semaglutide or Tirzepatide and concerned about gaining weight after discontinuing — then this episode is for you. Gaining fat is a real issue.

In this episode of The Medical Weight Loss Show, Dr. Andrea Walker, DNP, FNP-C—owner of Serenity Health & Wellness—breaks down the growing discussion highlighted in recent media coverage about “yo-yo” weight gain after stopping GLP-1 medications.

Many patients will experience weight regain—but what’s most concerning isn’t just the number on the scale. It’s how the body regains weight, often favoring fat over muscle, and what that means for long-term metabolic health.

Dr. Walker explains:
• Why appetite and hunger hormones rebound after stopping GLP-1s
• The science behind metabolic adaptation and weight regain
• How muscle loss during weight loss impacts body composition
• Why repeated weight cycling can worsen metabolic health
• The importance of strength training, protein intake, and maintenance planning
• How to create a sustainable, long-term weight loss strategy

This episode is a must-listen for anyone currently on GLP-1 medications, considering them, or struggling to maintain weight loss.

Because real success isn’t just losing weight—it’s keeping it off.

Recent headlines mention Ozempic and 3 deaths, leaving many patients wondering if these popular weight-loss medications are actually safe.

But what did the FDA really say?

In this episode of The Medical Weight Loss Show, Nurse Practitioner and weight loss specialist Dr. Andrea Walker breaks down the facts behind the recent news reports.

You’ll learn:

• Why adverse event reports do NOT prove a medication caused a death
• The difference between association and causation in drug safety reporting
• The role of compounded semaglutide vs FDA-approved medications
• What patients taking GLP-1 medications for weight loss or diabetes should know

This episode cuts through the media headlines and misinformation to provide a clear, fact-based explanation of how medication safety reporting works and what the current evidence actually shows about GLP-1 drugs.